An interim analysis of a validation study suggests that urine prostate cancer antigen 3 (PCA3) levels and urine TMPRSS2:ERG (T2:ERG) have additive utility in predicting clinically significant prostate tumor volume, and their use together may enhance the selection and monitoring of candidates with low-volume/low-grade disease for active surveillance.
Continuous androgen deprivation therapy shows better survival outcomes in men with metastatic prostate cancer
Continuous androgen deprivation therapy confers a survival advantage over intermittent therapy in men with metastatic prostate cancer.
Widespread PSA screening appears to lead to improvements in pathologic outcomes.
Treatment with the dual 5-alpha- reductase inhibitor dutasteride (Avodart) does not compromise the utility of PSA to detect progression of disease in patients with low-risk localized prostate cancer who are being managed with active surveillance.
Ureteroscopy has overtaken extracorporeal shock wave lithotripsy as the treatment of choice for kidney stones, Canadian researchers recently reported.
Observational data fail to support a role of 5-alpha-reductase inhibitors (5-ARIs) for secondary prevention of clinically significant prostate cancer in men with very low-risk disease.
Low-dose computed tomography scans reduce radiation exposure while maintaining diagnostic quality in patients with stage I testicular germ cell tumors being managed with surveillance following orchiectomy.
Dose titration of the vascular endothelial growth factor receptor inhibitor axitinib (Inlyta) to achieve therapeutic blood levels may be required for patients with metastatic renal cell carcinoma to derive optimal benefit from the drug as second-line therapy.
Single nucleotide polymorphisms of the carbonic anhydrase 9 gene are found frequently in patients with metastatic renal cell carcinoma, and predict prognosis and response to immunotherapy.
Measuring paired-like homeodomain transcription factor 2 methylation status may aid in predicting the risk of biochemical recurrence after radical prostatectomy.